Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 336

1.

ESCRT-III-driven piecemeal micro-ER-phagy remodels the ER during recovery from ER stress.

Loi M, Raimondi A, Morone D, Molinari M.

Nat Commun. 2019 Nov 7;10(1):5058. doi: 10.1038/s41467-019-12991-z.

2.

Identification and characterization of human interferon alpha inhibitors through a WISH cell line-based reporter gene assay.

Bürgi M, Hernández P, Cabrera M, Cerecetto H, González M, Kratje R, Raimondi A, Oggero M, Bollati-Fogolín M.

Bioorg Chem. 2019 Oct 28:103372. doi: 10.1016/j.bioorg.2019.103372. [Epub ahead of print]

PMID:
31699391
3.

Clathrin light chain A drives selective myosin VI recruitment to clathrin-coated pits under membrane tension.

Biancospino M, Buel GR, Niño CA, Maspero E, di Perrotolo RS, Raimondi A, Redlingshöfer L, Weber J, Brodsky FM, Walters KJ, Polo S.

Nat Commun. 2019 Oct 31;10(1):4974. doi: 10.1038/s41467-019-12855-6.

4.

Thymus Imaging Detection and Size Is Inversely Associated With Metabolic Syndrome and Frailty in People With HIV.

Guaraldi G, Franconi I, Milic J, Besutti G, Pintassilgo I, Scaglioni R, Ligabue G, Riva N, Raimondi A, Menozzi M, Carli F, Zona S, Santoro A, Malagoli A, Borghi V, Torricelli P, Cossarizza A, Mussini C.

Open Forum Infect Dis. 2019 Oct 4;6(10):ofz435. doi: 10.1093/ofid/ofz435. eCollection 2019 Oct.

5.

Sorafenib Versus Observation Following Radical Metastasectomy for Clear-cell Renal Cell Carcinoma: Results from the Phase 2 Randomized Open-label RESORT Study.

Procopio G, Apollonio G, Cognetti F, Miceli R, Milella M, Mosca A, Chiuri VE, Bearz A, Morelli F, Ortega C, Atzori F, Donini M, Ratta R, Raimondi A, Claps M, Martinetti A, Capitanio U, de Braud FG, Cappelletti V, Verzoni E.

Eur Urol Oncol. 2019 Nov;2(6):699-707. doi: 10.1016/j.euo.2019.08.011. Epub 2019 Sep 19.

PMID:
31542243
6.

Negative Hyperselection of Patients With RAS and BRAF Wild-Type Metastatic Colorectal Cancer Who Received Panitumumab-Based Maintenance Therapy.

Morano F, Corallo S, Lonardi S, Raimondi A, Cremolini C, Rimassa L, Murialdo R, Zaniboni A, Sartore-Bianchi A, Tomasello G, Racca P, Clavarezza M, Adamo V, Perrone F, Gloghini A, Tamborini E, Busico A, Martinetti A, Palermo F, Loupakis F, Milione M, Fucà G, Di Bartolomeo M, de Braud F, Pietrantonio F.

J Clin Oncol. 2019 Nov 20;37(33):3099-3110. doi: 10.1200/JCO.19.01254. Epub 2019 Sep 20.

PMID:
31539295
7.

Individual Patient Data Meta-Analysis of the Value of Microsatellite Instability As a Biomarker in Gastric Cancer.

Pietrantonio F, Miceli R, Raimondi A, Kim YW, Kang WK, Langley RE, Choi YY, Kim KM, Nankivell MG, Morano F, Wotherspoon A, Valeri N, Kook MC, An JY, Grabsch HI, Fucà G, Noh SH, Sohn TS, Kim S, Di Bartolomeo M, Cunningham D, Lee J, Cheong JH, Smyth EC.

J Clin Oncol. 2019 Sep 12:JCO1901124. doi: 10.1200/JCO.19.01124. [Epub ahead of print]

PMID:
31513484
8.

The Evaluation of Response to Immunotherapy in Metastatic Renal Cell Carcinoma: Open Challenges in the Clinical Practice.

Raimondi A, Randon G, Sepe P, Claps M, Verzoni E, de Braud F, Procopio G.

Int J Mol Sci. 2019 Aug 30;20(17). pii: E4263. doi: 10.3390/ijms20174263. Review.

9.

Advanced Fluorescent Polymer Probes for the Site-Specific Labeling of Proteins in Live Cells Using the HaloTag Technology.

Berki T, Bakunts A, Duret D, Fabre L, Ladavière C, Orsi A, Charreyre MT, Raimondi A, van Anken E, Favier A.

ACS Omega. 2019 Jul 30;4(7):12841-12847. doi: 10.1021/acsomega.9b01643. eCollection 2019 Jul 31.

10.

Somatostatin analogs in association with peptide receptor radionucleotide therapy in advanced well-differentiated NETs.

Prinzi N, Raimondi A, Maccauro M, Milione M, Garanzini E, Torchio M, Corti F, Nichetti F, Russo GL, Giacomelli L, Mazzaferro V, Bartolomeo MD, Seregni E, Braud F, Pusceddu S.

Future Oncol. 2019 Sep;15(26):3015-3024. doi: 10.2217/fon-2019-0138. Epub 2019 Aug 19.

PMID:
31424273
11.

Do biomarkers play a predictive role for response to novel immunotherapeutic agents in metastatic renal cell carcinoma?

Raimondi A, Sepe P, Claps M, Verzoni E, Procopio G.

Expert Opin Biol Ther. 2019 Nov;19(11):1107-1110. doi: 10.1080/14712598.2019.1651288. Epub 2019 Aug 6. No abstract available.

PMID:
31369337
12.

Maintenance Therapy With Panitumumab Alone vs Panitumumab Plus Fluorouracil-Leucovorin in Patients With RAS Wild-Type Metastatic Colorectal Cancer: A Phase 2 Randomized Clinical Trial.

Pietrantonio F, Morano F, Corallo S, Miceli R, Lonardi S, Raimondi A, Cremolini C, Rimassa L, Bergamo F, Sartore-Bianchi A, Tampellini M, Racca P, Clavarezza M, Berenato R, Caporale M, Antista M, Niger M, Smiroldo V, Murialdo R, Zaniboni A, Adamo V, Tomasello G, Giordano M, Petrelli F, Longarini R, Cinieri S, Falcone A, Zagonel V, Di Bartolomeo M, de Braud F.

JAMA Oncol. 2019 Jul 3. doi: 10.1001/jamaoncol.2019.1467. [Epub ahead of print]

13.

Anti-tumor Activity of the Type I PRMT Inhibitor, GSK3368715, Synergizes with PRMT5 Inhibition through MTAP Loss.

Fedoriw A, Rajapurkar SR, O'Brien S, Gerhart SV, Mitchell LH, Adams ND, Rioux N, Lingaraj T, Ribich SA, Pappalardi MB, Shah N, Laraio J, Liu Y, Butticello M, Carpenter CL, Creasy C, Korenchuk S, McCabe MT, McHugh CF, Nagarajan R, Wagner C, Zappacosta F, Annan R, Concha NO, Thomas RA, Hart TK, Smith JJ, Copeland RA, Moyer MP, Campbell J, Stickland K, Mills J, Jacques-O'Hagan S, Allain C, Johnston D, Raimondi A, Porter Scott M, Waters N, Swinger K, Boriack-Sjodin A, Riera T, Shapiro G, Chesworth R, Prinjha RK, Kruger RG, Barbash O, Mohammad HP.

Cancer Cell. 2019 Jul 8;36(1):100-114.e25. doi: 10.1016/j.ccell.2019.05.014. Epub 2019 Jun 27.

PMID:
31257072
14.

Cabozantinib in Renal Cell Carcinoma With Brain Metastases: Safety and Efficacy in a Real-World Population.

Peverelli G, Raimondi A, Ratta R, Verzoni E, Bregni M, Cortesi E, Cartenì G, Fornarini G, Facchini G, Buti S, Galli L, Tucci M, Prisciandaro M, Procopio G.

Clin Genitourin Cancer. 2019 Aug;17(4):291-298. doi: 10.1016/j.clgc.2019.05.002. Epub 2019 May 13.

PMID:
31178240
15.

Molecularly Distinct Clathrin-Coated Pits Differentially Impact EGFR Fate and Signaling.

Pascolutti R, Algisi V, Conte A, Raimondi A, Pasham M, Upadhyayula S, Gaudin R, Maritzen T, Barbieri E, Caldieri G, Tordonato C, Confalonieri S, Freddi S, Malabarba MG, Maspero E, Polo S, Tacchetti C, Haucke V, Kirchhausen T, Di Fiore PP, Sigismund S.

Cell Rep. 2019 Jun 4;27(10):3049-3061.e6. doi: 10.1016/j.celrep.2019.05.017.

16.

The role of metastasectomy in advanced renal cell carcinoma.

Apollonio G, Raimondi A, Verzoni E, Claps M, Sepe P, Pagani F, Ratta R, Montorsi F, De Braud FGM, Procopio G.

Expert Rev Anticancer Ther. 2019 Jul;19(7):603-611. doi: 10.1080/14737140.2019.1625772. Epub 2019 Jun 8.

PMID:
31159619
17.

Phagocytosis-shielded lentiviral vectors improve liver gene therapy in nonhuman primates.

Milani M, Annoni A, Moalli F, Liu T, Cesana D, Calabria A, Bartolaccini S, Biffi M, Russo F, Visigalli I, Raimondi A, Patarroyo-White S, Drager D, Cristofori P, Ayuso E, Montini E, Peters R, Iannacone M, Cantore A, Naldini L.

Sci Transl Med. 2019 May 22;11(493). pii: eaav7325. doi: 10.1126/scitranslmed.aav7325.

PMID:
31118293
18.

Investigating the interoceptive stimulus effects of injected menthol in rats.

Huynh YW, Raimondi A, Schuster C, Finkner A, Selleck C, Bevins RA.

Exp Clin Psychopharmacol. 2019 May 9. doi: 10.1037/pha0000295. [Epub ahead of print]

PMID:
31070425
19.

Prognostic Impact of Microsatellite Instability in Asian Gastric Cancer Patients Enrolled in the ARTIST Trial.

Miceli R, An J, Di Bartolomeo M, Morano F, Kim ST, Park SH, Choi MG, Lee JH, Raimondi A, Fucà G, Sohn TS, Bae JM, Kim S, Lim DH, Kang WK, Kim KM, Pietrantonio F, Lee J.

Oncology. 2019;97(1):38-43. doi: 10.1159/000499628. Epub 2019 May 2.

PMID:
31048579
20.

Metronomic Capecitabine With Cyclophosphamide Regimen in Unresectable or Relapsed Pseudomyxoma Peritonei.

Raimondi A, Corallo S, Niger M, Antista M, Randon G, Morano F, Milione M, Kusamura S, Baratti D, Guaglio M, Cremolini C, Marmorino F, Di Bartolomeo M, Deraco M, De Braud F, Pietrantonio F.

Clin Colorectal Cancer. 2019 Jun;18(2):e179-e190. doi: 10.1016/j.clcc.2019.03.002. Epub 2019 Apr 1.

PMID:
31023524
21.

Real-world efficacy and safety of nivolumab in previously-treated metastatic renal cell carcinoma, and association between immune-related adverse events and survival: the Italian expanded access program.

Verzoni E, Cartenì G, Cortesi E, Giannarelli D, De Giglio A, Sabbatini R, Buti S, Rossetti S, Cognetti F, Rastelli F, Sobrero A, Turci D, Sternberg CN, Porta C, Cappuzzo F, Tortora G, Tassinari D, Panni S, Pazzola A, Surico G, Raimondi A, De Giorgi U, Procopio G; Italian Nivolumab Renal Cell Cancer Early Access Program group.

J Immunother Cancer. 2019 Apr 3;7(1):99. doi: 10.1186/s40425-019-0579-z.

22.

Inadequate BiP availability defines endoplasmic reticulum stress.

Vitale M, Bakunts A, Orsi A, Lari F, Tadè L, Danieli A, Rato C, Valetti C, Sitia R, Raimondi A, Christianson JC, van Anken E.

Elife. 2019 Mar 14;8. pii: e41168. doi: 10.7554/eLife.41168.

23.

Prognostic impact of ATM mutations in patients with metastatic colorectal cancer.

Randon G, Fucà G, Rossini D, Raimondi A, Pagani F, Perrone F, Tamborini E, Busico A, Peverelli G, Morano F, Niger M, Antista M, Corallo S, Saggio S, Borelli B, Zucchelli G, Milione M, Pruneri G, Di Bartolomeo M, Falcone A, de Braud F, Cremolini C, Pietrantonio F.

Sci Rep. 2019 Feb 27;9(1):2858. doi: 10.1038/s41598-019-39525-3.

24.

Redundant and nonredundant organismal functions of EPS15 and EPS15L1.

Milesi C, Alberici P, Pozzi B, Oldani A, Beznoussenko GV, Raimondi A, Soppo BE, Amodio S, Caldieri G, Malabarba MG, Bertalot G, Confalonieri S, Parazzoli D, Mironov AA, Tacchetti C, Di Fiore PP, Sigismund S, Offenhäuser N.

Life Sci Alliance. 2019 Jan 28;2(1). pii: e201800273. doi: 10.26508/lsa.201800273. Print 2019 Feb.

25.

Refining the selection of patients with metastatic colorectal cancer for treatment with temozolomide using proteomic analysis of O6-methylguanine-DNA-methyltransferase.

Schwartz S, Szeto C, Tian Y, Cecchi F, Corallo S, Calegari MA, Di Bartolomeo M, Morano F, Raimondi A, Fucà G, Martinetti A, De Pascalis I, Martini M, Belfiore A, Milione M, Orlandi A, Barault L, Barone C, de Braud F, Di Nicolantonio F, Benz S, Hembrough T, Pietrantonio F.

Eur J Cancer. 2019 Jan;107:164-174. doi: 10.1016/j.ejca.2018.11.016. Epub 2018 Dec 19.

PMID:
30579113
26.

A selective ER-phagy exerts procollagen quality control via a Calnexin-FAM134B complex.

Forrester A, De Leonibus C, Grumati P, Fasana E, Piemontese M, Staiano L, Fregno I, Raimondi A, Marazza A, Bruno G, Iavazzo M, Intartaglia D, Seczynska M, van Anken E, Conte I, De Matteis MA, Dikic I, Molinari M, Settembre C.

EMBO J. 2019 Jan 15;38(2). pii: e99847. doi: 10.15252/embj.201899847. Epub 2018 Dec 17.

27.

Perioperative Bevacizumab-based Triplet Chemotherapy in Patients With Potentially Resectable Colorectal Cancer Liver Metastases.

Pietrantonio F, Cotsoglou C, Fucà G, Lo Vullo S, Nichetti F, Milione M, Coppa J, Vaiani M, Alessi A, Prisciandaro M, Droz-Dit Busset M, Morano F, Corallo S, Lazzati S, Antista M, Mennitto A, Randon G, Raimondi A, Belfiore A, Padovano B, Perrone F, Mariani L, Di Bartolomeo M, de Braud F, Mazzaferro V.

Clin Colorectal Cancer. 2019 Mar;18(1):34-43.e6. doi: 10.1016/j.clcc.2018.11.004. Epub 2018 Nov 24.

PMID:
30558859
28.

Targeting the PI3K/AKT/mTOR pathway in biliary tract cancers: A review of current evidences and future perspectives.

Corti F, Nichetti F, Raimondi A, Niger M, Prinzi N, Torchio M, Tamborini E, Perrone F, Pruneri G, Di Bartolomeo M, de Braud F, Pusceddu S.

Cancer Treat Rev. 2019 Jan;72:45-55. doi: 10.1016/j.ctrv.2018.11.001. Epub 2018 Nov 10. Review.

PMID:
30476750
29.

ER-to-lysosome-associated degradation of proteasome-resistant ATZ polymers occurs via receptor-mediated vesicular transport.

Fregno I, Fasana E, Bergmann TJ, Raimondi A, Loi M, Soldà T, Galli C, D'Antuono R, Morone D, Danieli A, Paganetti P, van Anken E, Molinari M.

EMBO J. 2018 Sep 3;37(17). pii: e99259. doi: 10.15252/embj.201899259. Epub 2018 Aug 3.

30.

Genomic markers of resistance to targeted treatments in gastric cancer: potential new treatment strategies.

Raimondi A, Nichetti F, Peverelli G, Di Bartolomeo M, De Braud F, Pietrantonio F.

Pharmacogenomics. 2018 Aug 1;19(13):1047-1068. doi: 10.2217/pgs-2018-0077. Epub 2018 Jul 25. Review.

PMID:
30041572
31.

Temozolomide and irinotecan (TEMIRI regimen) as salvage treatment of irinotecan-sensitive advanced colorectal cancer patients bearing MGMT methylation.

Morano F, Corallo S, Niger M, Barault L, Milione M, Berenato R, Moretto R, Randon G, Antista M, Belfiore A, Raimondi A, Nichetti F, Martinetti A, Battaglia L, Perrone F, Pruneri G, Falcone A, Di Bartolomeo M, de Braud F, Di Nicolantonio F, Cremolini C, Pietrantonio F.

Ann Oncol. 2018 Aug 1;29(8):1800-1806. doi: 10.1093/annonc/mdy197.

PMID:
29860358
32.

Small molecule inhibitors and CRISPR/Cas9 mutagenesis demonstrate that SMYD2 and SMYD3 activity are dispensable for autonomous cancer cell proliferation.

Thomenius MJ, Totman J, Harvey D, Mitchell LH, Riera TV, Cosmopoulos K, Grassian AR, Klaus C, Foley M, Admirand EA, Jahic H, Majer C, Wigle T, Jacques SL, Gureasko J, Brach D, Lingaraj T, West K, Smith S, Rioux N, Waters NJ, Tang C, Raimondi A, Munchhof M, Mills JE, Ribich S, Porter Scott M, Kuntz KW, Janzen WP, Moyer M, Smith JJ, Chesworth R, Copeland RA, Boriack-Sjodin PA.

PLoS One. 2018 Jun 1;13(6):e0197372. doi: 10.1371/journal.pone.0197372. eCollection 2018.

33.

Entering the third decade of experience with octreotide LAR in neuroendocrine tumors: A review of current knowledge.

Pusceddu S, Prinzi N, Raimondi A, Corti F, Buzzoni R, Di Bartolomeo M, Seregni E, Maccauro M, Coppa J, Milione M, Mazzaferro V, de Braud F.

Tumori. 2019 Apr;105(2):113-120. doi: 10.1177/0300891618765362. Epub 2018 Apr 6. Review.

PMID:
29714658
34.

Prolonged activity and toxicity of sirolimus in a patient with metastatic renal perivascular epithelioid cell tumor: a case report and literature review.

Raimondi A, Colombo F, Pintarelli G, Morosi C, Renne SL, Frezza AM, Saponara M, Dei Tos AP, Mazzocchi A, Provenzano S, Casali PG, Stacchiotti S.

Anticancer Drugs. 2018 Jul;29(6):589-595. doi: 10.1097/CAD.0000000000000634. Review.

PMID:
29668485
35.

The Role of Mesothelin as a Diagnostic and Therapeutic Target in Pancreatic Ductal Adenocarcinoma: A Comprehensive Review.

Nichetti F, Marra A, Corti F, Guidi A, Raimondi A, Prinzi N, de Braud F, Pusceddu S.

Target Oncol. 2018 Jun;13(3):333-351. doi: 10.1007/s11523-018-0567-0. Review.

PMID:
29656320
36.

Palliative Sedation in Terminal Cancer Patients Admitted to Hospice or Home Care Programs: Does the Setting Matter? Results From a National Multicenter Observational Study.

Caraceni A, Speranza R, Spoldi E, Ambroset CS, Canestrari S, Marinari M, Marzi AM, Orsi L, Piva L, Rocchi M, Valenti D, Zeppetella G, Zucco F, Raimondi A, Matos LV, Brunelli C; Italian Society of Palliative Care Study Group on Palliative Sedation in Adult Cancer Patients.

J Pain Symptom Manage. 2018 Jul;56(1):33-43. doi: 10.1016/j.jpainsymman.2018.03.008. Epub 2018 Mar 13.

PMID:
29548893
37.

Diet and supplements in cancer prevention and treatment: Clinical evidences and future perspectives.

Vernieri C, Nichetti F, Raimondi A, Pusceddu S, Platania M, Berrino F, de Braud F.

Crit Rev Oncol Hematol. 2018 Mar;123:57-73. doi: 10.1016/j.critrevonc.2018.01.002. Epub 2018 Feb 2. Review.

PMID:
29482780
38.

Identification of a membrane-less compartment regulating invadosome function and motility.

Sala K, Raimondi A, Tonoli D, Tacchetti C, de Curtis I.

Sci Rep. 2018 Jan 18;8(1):1164. doi: 10.1038/s41598-018-19447-2.

39.

Impaired autophagy bridges lysosomal storage disease and epithelial dysfunction in the kidney.

Festa BP, Chen Z, Berquez M, Debaix H, Tokonami N, Prange JA, Hoek GV, Alessio C, Raimondi A, Nevo N, Giles RH, Devuyst O, Luciani A.

Nat Commun. 2018 Jan 11;9(1):161. doi: 10.1038/s41467-017-02536-7.

40.

Response to isolated limb perfusion and chemotherapy with epirubicin plus ifosfamide in a metastatic malignant ossifying fibromyxoid tumor.

Provenzano S, Raimondi A, Bertulli RM, Colia V, Renne SL, Collini P, Dagrada G, Callegaro D, Fiore M, Greco FG, Casali PG.

Clin Sarcoma Res. 2017 Dec 28;7:20. doi: 10.1186/s13569-017-0086-2. eCollection 2017.

41.

Identification of a CARM1 Inhibitor with Potent In Vitro and In Vivo Activity in Preclinical Models of Multiple Myeloma.

Drew AE, Moradei O, Jacques SL, Rioux N, Boriack-Sjodin AP, Allain C, Scott MP, Jin L, Raimondi A, Handler JL, Ott HM, Kruger RG, McCabe MT, Sneeringer C, Riera T, Shapiro G, Waters NJ, Mitchell LH, Duncan KW, Moyer MP, Copeland RA, Smith J, Chesworth R, Ribich SA.

Sci Rep. 2017 Dec 21;7(1):17993. doi: 10.1038/s41598-017-18446-z.

42.

Ratiometric sensing of BiP-client versus BiP levels by the unfolded protein response determines its signaling amplitude.

Bakunts A, Orsi A, Vitale M, Cattaneo A, Lari F, Tadè L, Sitia R, Raimondi A, Bachi A, van Anken E.

Elife. 2017 Dec 18;6. pii: e27518. doi: 10.7554/eLife.27518.

43.

A novel SYN1 missense mutation in non-syndromic X-linked intellectual disability affects synaptic vesicle life cycle, clustering and mobility.

Guarnieri FC, Pozzi D, Raimondi A, Fesce R, Valente MM, Delvecchio VS, Van Esch H, Matteoli M, Benfenati F, D'Adamo P, Valtorta F.

Hum Mol Genet. 2017 Dec 1;26(23):4699-4714. doi: 10.1093/hmg/ddx352.

PMID:
28973667
44.

Genome editing for scalable production of alloantigen-free lentiviral vectors for in vivo gene therapy.

Milani M, Annoni A, Bartolaccini S, Biffi M, Russo F, Di Tomaso T, Raimondi A, Lengler J, Holmes MC, Scheiflinger F, Lombardo A, Cantore A, Naldini L.

EMBO Mol Med. 2017 Nov;9(11):1558-1573. doi: 10.15252/emmm.201708148.

45.

EZH2 Inhibition by Tazemetostat Results in Altered Dependency on B-cell Activation Signaling in DLBCL.

Brach D, Johnston-Blackwell D, Drew A, Lingaraj T, Motwani V, Warholic NM, Feldman I, Plescia C, Smith JJ, Copeland RA, Keilhack H, Chan-Penebre E, Knutson SK, Ribich SA, Raimondi A, Thomenius MJ.

Mol Cancer Ther. 2017 Nov;16(11):2586-2597. doi: 10.1158/1535-7163.MCT-16-0840. Epub 2017 Aug 23.

46.

Lung ultrasound in internal medicine: A bedside help to increase accuracy in the diagnosis of dyspnea.

Perrone T, Maggi A, Sgarlata C, Palumbo I, Mossolani E, Ferrari S, Melloul A, Mussinelli R, Boldrini M, Raimondi A, Cabassi A, Salinaro F, Perlini S.

Eur J Intern Med. 2017 Dec;46:61-65. doi: 10.1016/j.ejim.2017.07.034. Epub 2017 Aug 6.

PMID:
28793969
47.

BAP1 regulates IP3R3-mediated Ca2+ flux to mitochondria suppressing cell transformation.

Bononi A, Giorgi C, Patergnani S, Larson D, Verbruggen K, Tanji M, Pellegrini L, Signorato V, Olivetto F, Pastorino S, Nasu M, Napolitano A, Gaudino G, Morris P, Sakamoto G, Ferris LK, Danese A, Raimondi A, Tacchetti C, Kuchay S, Pass HI, Affar EB, Yang H, Pinton P, Carbone M.

Nature. 2017 Jun 22;546(7659):549-553. doi: 10.1038/nature22798. Epub 2017 Jun 14.

48.

Reticulon 3-dependent ER-PM contact sites control EGFR nonclathrin endocytosis.

Caldieri G, Barbieri E, Nappo G, Raimondi A, Bonora M, Conte A, Verhoef LGGC, Confalonieri S, Malabarba MG, Bianchi F, Cuomo A, Bonaldi T, Martini E, Mazza D, Pinton P, Tacchetti C, Polo S, Di Fiore PP, Sigismund S.

Science. 2017 May 12;356(6338):617-624. doi: 10.1126/science.aah6152.

49.

Autophagy regulates UBC9 levels during viral-mediated tumorigenesis.

Mattoscio D, Casadio C, Miccolo C, Maffini F, Raimondi A, Tacchetti C, Gheit T, Tagliabue M, Galimberti VE, De Lorenzi F, Pawlita M, Chiesa F, Ansarin M, Tommasino M, Chiocca S.

PLoS Pathog. 2017 Mar 2;13(3):e1006262. doi: 10.1371/journal.ppat.1006262. eCollection 2017 Mar.

50.

The amyloidogenic light chain is a stressor that sensitizes plasma cells to proteasome inhibitor toxicity.

Oliva L, Orfanelli U, Resnati M, Raimondi A, Orsi A, Milan E, Palladini G, Milani P, Cerruti F, Cascio P, Casarini S, Rognoni P, Touvier T, Marcatti M, Ciceri F, Mangiacavalli S, Corso A, Merlini G, Cenci S.

Blood. 2017 Apr 13;129(15):2132-2142. doi: 10.1182/blood-2016-08-730978. Epub 2017 Jan 27.

PMID:
28130214

Supplemental Content

Loading ...
Support Center